Group 1 - The stock of Wangshan Wangshui-B (02630) experienced a decline of nearly 7% after a previous increase of nearly 11%, currently trading at 101.4 HKD with a transaction volume of 11.0993 million HKD [1] - A significant research finding was published by the Wuhan Institute of Virology, confirming that the oral nucleoside drug VV116 has notable antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this highly lethal emerging infectious disease [1] - VV116, developed by Wangshan Wangshui, is an oral nucleoside drug with broad-spectrum antiviral potential, already approved for use against SARS-CoV-2 in China (marketed as Mindwei®) and Uzbekistan (marketed as Mindvy®) [1] Group 2 - Industry expert Li Changcheng analyzed that if the efficacy of the drug against the Nipah virus is confirmed, pharmaceutical companies may expand the drug's usage, leading to greater commercial benefits, as extending indications on existing drugs incurs the lowest costs and yields the highest returns [2] - It is noted that while there is theoretical support for nucleoside drugs inhibiting the Nipah virus, the effectiveness against the current Indian strain of the virus requires clinical validation [2]
港股异动 | 旺山旺水-B(02630)回落近7% 昨日受尼帕疫情催化大涨近11%